The Kinected 2 Study is evaluating the safety, tolerability, and persistence of effect of valbenazine (or INGREZZA®) after stopping valbenazine treatment. If you are an adult between the ages of 18 and 85 (inclusive) who has been diagnosed with schizophrenia, schizoaffective disorder, or mood disorder, and have medication-induced tardive dyskinesia, and would like to be part of the study, please complete the questionnaire to determine your eligibility.
By answering the following questions, you agree to have your information retained for the duration of the study, and to receive phone or email communication related to this clinical research study.
This website uses Secure Socket Layer technology and encryption methods to protect personal health information. If you’d like to know more about this, click here.